Atea Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Atea Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Atea Pharmaceuticals Inc recorded a cumulative net loss of $-165 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -50.85%.

However, within the Healthcare sector 598 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3947, from total ROA ranking in the first quarter of 2026 at 4494.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-4.19 %	-39.23 %	-32.1 %	-60.71 %	-23.13 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-165	-170	-158	-147	-136
Return On Assets (TTM)	-50.85 %	-51.5 %	-42.54 %	-35.9 %	-25.12 %
AVIR's Total Ranking	# 3947	# 4494	# 3852	# 3798	# 3836
Total Assets (TTM) in million	375	267	315	343	392
Seq. Total Assets Change	40.48 %	-15.27 %	-8.02 %	-12.49 %	-10.89 %
Seq. Net Income Change	-	-	-	-	-

AVIR's 5 Years Annual ROA >> Back to AVIR Management Effectiveness >> Compare AVIR ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 266
Sector	# 599
Overall	# 3968

Return On Assets Statistics
High	Average	Low
14.56 %	-18.43 %	-57.12 %
(Dec 31 2021)		(Jun 30 2026)

News about Atea Pharmaceuticals Inc Return on Assets ROA

Atea Pharmaceuticals Trials and Triumphs in the Race Against COVID-19 and Hepatitis C,

Summary of Atea Pharmaceuticals’ Recent DevelopmentsAtea Pharmaceuticals, Inc. a prominent clinical-stage biopharmaceutical company focused on developing oral antiviral therapeutics, has recently released updates related to two ongoing clinical trials involving its lead compound, bemnifosbuvir. These updates highlight both challenges in the treatment of COVID-19 and promising advancements in combating hepatitis C. SUNRISE-3 Trial OutcomesOn September 13, 2024, Atea announced results from its global Phase 3 SUNRISE-3 trial, which aimed to evaluate the efficacy of bemnifosbuvir, an oral nucleotide polymerase inhibitor, for treating COVID-19. The trial enrolled 2,221 high-risk patients with mild to moderate disease in a monotherapy cohort. Unfortunately, the trial did not achieve its primary endpoint: demonstrating a statistically significant reduction in all-cause hospitalization or death by Day 29 compared to placebo. Despite these disappointing results, bemnifosbuvir exhibited a favorable safety profile, being generally safe and well-tolerated by participants.

Financial Statements
Atea Pharmaceuticals Inc 's Assets	$ 375 million	AVIR's Balance sheet
Atea Pharmaceuticals Inc 's Income	$ -33 million	Quarterly AVIR's Income Statement
AVIR's Income by Division		See AVIR's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-32.1 %	-21.81 %	-10.8 %	-13.88 %	-10.51 %
Total Assets in million	315	464	594	666	773
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-158	-168	-136	-116	121
Annual Return On Assets	-50.23 %	-36.27 %	-22.9 %	-17.41 %	15.68 %

AVIR's 5 Years Annual ROA >> Back to AVIR Management Effectiveness >> Compare AVIR ROA to its Competitors

More Return On Assets Ratios
AVIR's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AVIR's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AVIR's Competitors
Subscribers only: Roa for Atea Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for AVIR's Customers

You may also want to know
AVIR's Roi	AVIR's Inventory Turnover Ratio	AVIR's Growth Rates	AVIR's Dividend Comparisons
	AVIR's Profitability Ratios	AVIR's Asset Turnover Ratio	AVIR's Dividend Growth
AVIR's Roe	AVIR's Valuation Ratios	AVIR's Financial Strength Ratios	AVIR's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-03T23:33:26+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.